Osso VR, which uses VR simulations to train surgeons, raises a $66M Series C led by Oak HC/FT, bringing its total funding to about $109M
Context & Ripple Effects
Osso VR's raise caps a fast escalation: the company went from a $14M Series A built on Oculus Quest headsets in 2020 to a $27M round led by GSR Ventures in mid-2021, and now a $66M Series C that roughly triples its total funding to about $109M.
The new lead, Oak HC/FT, is a healthcare-specialist investor, which matters because Osso VR sits in a medical-VR cluster that has been raising steadily on its own cadence — AppliedVR's $36M Series B for chronic-pain therapeutics and Activ Surgical's $15M round for real-time surgical intelligence preceded it, with rival simulation platform FundamentalVR following months later.
First-order effects
- Osso VR gains roughly $66M of runway to scale its surgeon-training simulations beyond the Oculus Quest-based platform it launched with, with a healthcare-focused lead investor signaling institutional conviction in the category.
- Oak HC/FT now holds a position at the top of the medical-VR training stack, putting it alongside GSR Ventures as a repeat backer of the company's trajectory from Series A to Series C.
Second-order effects
- FundamentalVR's $20M raise months later shows competitors answering with their own capital — cross-platform simulation positioning against Osso VR's headset-based approach, forcing both to differentiate on content breadth rather than hardware.
- Medical device makers, the natural buyers of surgical training content, gain multiple funded vendors to choose from, shifting pricing leverage toward customers as the category fills out.
Third-order effects
- If the funding pattern holds across Osso VR, AppliedVR, Activ Surgical, and FundamentalVR, VR splits into distinct healthcare verticals — clinician training, patient therapeutics, intraoperative intelligence — each with dedicated capital rather than one general-purpose 'medical VR' market.
- Surgical training becomes an institutional procurement line item: hospitals and device companies evaluating simulation vendors as standard infrastructure, which would entrench early-funded players like Osso VR against later entrants.
The trend: Healthcare VR is separating from consumer VR into funded vertical niches — training, therapeutics, and surgical intelligence — with specialist investors like Oak HC/FT setting the pace.